Search

everythinglearnresearchcommunity

for

Search:↓

A COVID-19 infected patient with chronic kidney disease experienced worsened kidney function, hair loss, and unexpected wart clearance.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Lotion with fucoidan from brown seaweed improved skin and reduced allergy symptoms in mice with dermatitis.

New therapies are being developed that target integrin pathways to treat various diseases.

COVID-19 may trigger severe skin flare-ups in people with autoimmune conditions like lupus.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.

Oral tofacitinib successfully treated total body hair loss in one patient.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

A girl developed vitiligo and psoriasis after hepatitis B treatment, and stopping the treatment didn't help.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

A girl with a rare genetic condition affecting hair and nails also developed a common type of hair loss, suggesting a possible genetic link.

The treatment might help COVID-19 related hair loss, but more research is needed.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

The study found that alopecia areata is strongly linked to autoimmune diseases and may indicate a genetic predisposition to such conditions.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

QR678 Neo® improved seborrheic dermatitis symptoms in a small group of patients.

Alopecia areata is an autoimmune disease where T cells attack hair follicles.

The L412F variant of TLR3 is linked to skin infections, more viral infections, and autoimmune issues.

Hair follicle cells help protect against immune attacks by regulating T-cell activity.

Methotrexate is a promising and safe treatment for severe alopecia areata, with better results when combined with corticosteroids.